Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3360

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3360
---
,831
4,276,790 281,736 26,758,574

(2)
Elizabeth Ng, M.D.

30,342,761
2,414,667 274,929 26,758,574

(3)
Jonathan Kurtis, M.D., Ph.D

30,625,072
2,125,038 282,247 26,758,574

(4)
Michael Peterson

30,520,515
2,210,232 301,610 26,758,574

2.
Approval of a. Reverse Split of issued and outstanding shares of common stock approval in a range of 1:2 to 1:250.

For
Against Abstain

43,708,050
15,757,223 325,658

3.
Approval of 2025 Equity Compensation Plan.

For
Against Abstain Broker Non-Vote

28,773,654
4,136,878 121,825 26,758,574

4.
Ratification of Auditors Berkowitz Pollack & Brandt as our independent registered public accounting firm for the year ending December
31, 2025.

For
Against Abstain

55,487,338
3,329,999 973,594

5.
Approve a non-binding advisory vote regarding the compensation paid to our Named Executive Officers
(“Say-On-Pay”)

For
Against Abstain Broker Non-Vote

29,233,497
3,583,347 215,513 26,758,574

6.
Approve a non-binding advisory vote regarding the frequency of holding our Say-On-Pay vote.

Three
Years Two Years One Year Abstain Broker Non-Vote

27,236,885
3,242,231 1,788,193 765,048 26,758,574

As
previously disclosed, at the Meeting, the following directors either determined to not stand for election or resigned: Michelle Berrey
(who also resigned as CEO), Jack Elias, Bill Owens, Suren Ajjarapu and Amy Griffith.

11

Our
Strategy and Competitive Strengths

Our
goal is to facilitate the flow of academic discoveries from bench-to-bedside by efficiently carrying out the translational and clinical
development required to advance them commercially. The number of potential opportunities at research universities and medical centers
is large but only a small fraction of these opportunities is currently tapped by venture